DANA DELASKI: Open Payments
NPI 1467753772 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$12,976 in 175 payments from 45 companies in 2025. Trend: 2023 $40,084 · 2024 $12,552 · 2025 $12,976
Speaker / faculty: $6,075Food & beverage: $3,335Travel & lodging: $1,874Consulting: $1,693
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 31 | $8,379 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $1,501 |
| Celgene Corporation | 13 | $283 |
| Novartis Pharmaceuticals Corporation | 17 | $280 |
| Alexion Pharmaceuticals, Inc. | 3 | $221 |
| Janssen Biotech, Inc. | 11 | $187 |
| AstraZeneca Pharmaceuticals LP | 9 | $168 |
| ABBVIE INC. | 6 | $130 |
| Rigel Pharmaceuticals, Inc. | 3 | $116 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
Products named: Jakafi, REBLOZYL, ULTOMIRIS, TALVEY, TAVALISSE, Venclexta, KEYTRUDA, SARCLISA.
Industry payments across MS — which companies pay providers there.
